Clinical Trial Update: Study to Evaluate the Safety and Pharmacokinetics of SPI-1005 [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 study evaluating the safety and pharmacokinetics of SPI-1005 in participants with hearing loss and cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hearing Loss

Drugs mentioned

• SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Hearing Loss, Cancer | Phase 1 | Status: COMPLETED